BIO Letter to Congressional Leadership on the Give Kids a Chance Act & Reauthorization of the Pediatric Priority Review Voucher Program (PPRV)
March 7, 2025
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review Voucher Program (PPRV) is reauthorized. This program will provide greater certainty to small biotech companies, but more importantly, hope to children and families living with rare diseases.
Download Full Comments Below
2025-03-07 Letter from John F. Crowley to House and Senate Leadership
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review Voucher Program (PPRV) is reauthorized. This program will provide greater certainty to small biotech companies, but more importantly, hope to children and families living with rare diseases.